Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine. It induces cranial vessel constriction and inhibits the release of pro-inflammatory neuropeptides. It is available as standard tablets and orally disintegrating tablets (ODTs). ## Primary Indications Acute treatment of migraine with or without aura in adults and pediatric patients (aged 6 to 17 years). ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg at the onset of migraine. * **Dosing Interval:** If the migraine recurs or a partial response is observed, wait at least 2 hours before a second dose. * **Maximum Dose:** 30 mg in a 24-hour period. * **Note:** Use the 5 mg dose for patients taking propranolol (due to increased rizatriptan plasma concentrations). ## Pediatric Dosing (Aged 6–17 years) * **Weight < 40 kg:** 5 mg single dose. * **Weight ≥ 40 kg:** 10 mg single dose. * **Maximum:** Do not exceed one dose per 24-hour period. Safety data for multiple doses in pediatric patients within 24 hours is limited. ## Dose Adjustments * **Propranolol Use:** Limit maximum daily dose to 15 mg (three 5 mg doses) due to pharmacokinetic interactions. * **Hepatic/Renal Impairment:** Use with caution; consider 5 mg initial dose in patients with mild-to-moderate impairment. Avoid in severe hepatic impairment. ## Contraindications * History of ischemic heart disease, coronary artery vasospasm (Prinzmetal’s angina), or symptomatic Wolff-Parkinson-White syndrome. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease or ischemic bowel disease. * Uncontrolled hypertension. * Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. * Use within 14 days of monoamine oxidase inhibitor (MAOI) therapy. ## Adverse Effects * **Common:** Dizziness, somnolence, asthenia/fatigue, paresthesia. * **Serious:** Coronary artery vasospasm, myocardial infarction, arrhythmias, serotonin syndrome (especially when combined with SSRIs/SNRIs), and medication-overuse headache. ## Key Drug Interactions * **MAOIs:** Significantly increase rizatriptan blood levels; co-administration is contraindicated. * **Propranolol:** Increases rizatriptan AUC and Cmax; requires dosage adjustment. * **SSRIs/SNRIs:** Risk of serotonin syndrome; monitor for symptoms (agitation, tachycardia, hyperreflexia). * **Ergot-type medications:** Prolonged vasospastic effects; wait 24 hours between administrations. ## Monitoring * Assess cardiovascular status prior to first use in patients with significant risk factors. * Monitor for signs of serotonin syndrome. * Evaluate frequency of use to prevent medication-overuse headache. ## Clinical Pearls * **ODT Formulation:** The ODT formulation does not require water; the blister pack should be dry when handling (do not push through foil). * **Time to Effect:** Efficacy is generally observed within 30 to 60 minutes. * **Ineffectiveness:** If no response is observed after the first dose, the diagnosis of migraine should be reconsidered before attempting a second dose for the same attack. * **Dosing Limits:** Adherence to the 30 mg maximum in adults is critical to avoid toxicity. *** *Disclaimer: This information is for educational purposes only. Always verify current prescribing information, institutional protocols, and specific patient safety contraindications via official drug labels or clinical drug information databases (e.g., Lexicomp, Micromedex) before prescribing or administering medication.*